Private Equity's $4.2 Billion Dental Bet Is Getting Nervous

Fifty-plus DSO sale processes got pulled off the market starting in mid-2022, and most of them never came back. Dykema's 2025 M&A Outlook calls this year the "Year of the Muted Recovery", which is law-firm language for a simple fact: the people who bought your colleague's practice at seven times earnings in 2021 cannot sell their own platform today at a price they're willing to accept. They are still buying. They are buying smaller, slower, and cheaper, and they are buying from you.

Our view: for most single-site owners collecting between $1M and $2M, waiting three more years now beats selling into this market, and the headline multiple you were quoted at a study club in 2021 is not coming back in time to matter. That's a claim a lot of owners and every broker will argue with. Here's the case.

Dental Is Still the Busiest Aisle in the Store

Start with the part that isn't in doubt. Dental led every healthcare sector in private equity deal count last year, with at least 161 PE dental deals in 2024, up 10.3% from 2023, plus at least 22 more in August 2025 alone. The same report cites a Health Affairs finding that PE affiliation among dental practices nearly doubled, from 6.6% in 2015 to 12.8% in 2021.

So demand is real. The confusion starts when owners read deal count as deal quality. A high transaction count with stalled exits is not a hot market, it's a market where capital has nowhere else to go. Dykema's read is specific on this point: none of the expected recovery drivers fully arrived, not rate cuts, not the inflation easing everyone penciled in, and the larger deals stayed stuck while only the 1-to-5-office transactions kept moving at a steady clip.

Read that again as a seller. The deals still clearing are the small ones. The buyers clearing them are platforms that cannot refinance or exit at the valuation their 2021 investment committee approved. You are not selling a practice into a growth story anymore. You're selling into someone else's refinancing problem, and the terms reflect it.

The Multiple Isn't the Price, and Rollover Isn't Money

Here's the specific mistake, and it's made most often by owners aged 55 to 63 with one location, strong hygiene, and a broker letter in the mail pile. They hear "7x EBITDA" and they do the multiplication. They do not do the subtraction.

Three subtractions get them.

• Adjusted EBITDA is not your profit. The buyer recalculates your earnings after replacing your clinical production with market-rate associate compensation. Your take-home is not the input. Your business's earnings without you are.
• Rollover equity is not cash. A 20% to 40% equity roll is standard, and it is not a deposit on a certainty. It's a second, unhedged bet on a platform that, by Dykema's own count, may be one of the ones that can't sell.
• Earnouts are priced in the buyer's favor. If your number depends on hitting production targets under new management, new fee schedules, and a new scheduling system, you are underwriting their integration risk at your own expense.

The owners who get hurt worst are not the ones who sold cheap. They're the ones who sold at a good headline number, rolled 30% into the platform, and found out in year four that the platform's lenders got paid before they did. We wouldn't take that deal at today's exit visibility. Not at seven times, and not at eight.

A $1.4 Million Practice Loses $524,000 on Two Turns

Numbers, because the abstraction is where owners lose money.

Take a general practice collecting $1,400,000 a year. The owner produces $900,000 of that, hygiene and an associate cover the rest. Overhead excluding all owner compensation runs 62%, or $868,000. To replace the owner's chair time, a buyer budgets associate comp at 30% of that $900,000 in production, or $270,000. Adjusted EBITDA is therefore $1,400,000 minus $868,000 minus $270,000, which is $262,000.

At the 2021 story multiple of seven times, that's an enterprise value of $1,834,000. At the five times that single-site practices are actually clearing in a muted market, it's $1,310,000. Two turns of multiple compression cost this owner $524,000 on an identical practice with identical charts.

Now layer the rollover. Suppose the owner gets the better deal, $1,834,000, and rolls 30% of it, so $550,200 stays in platform equity. If the platform eventually exits at a 35% haircut to the valuation it carried when the owner rolled in, which is a mild outcome for a sponsor that held three years past its target window, that stake is worth $357,630. The paper loss is $192,570 on money the owner was told was the upside.

Against that, consider just staying. The practice throws off $262,000 of owner earnings above an associate's market comp. Hold five more years and that's $1,310,000 in cash flow the owner controls, with no earnout, no integration, and no lender ahead of them in line. That figure alone equals the full five-times sale price, and the owner still has a practice to sell at the end of it.

That math is why we'd tell most owners in this profile to keep the keys. The sale converts a known annuity into an unknown single bet on a sponsor's exit window. The only way the trade works is if the multiple is genuinely high and the cash portion at closing is genuinely large. In a market with fifty-plus abandoned sale processes behind it, that combination is rare and getting rarer.

11% Is a Share, Not a Trend Line

Owners sell out of fear as often as greed, and the fear is usually that consolidation is about to make independent practice impossible. The workforce data does not support the panic. In 2024, 11% of the 202,485 U.S. dentists worked in practices with 100 or more locations, while 34% were still solo practitioners, per the ADA Health Policy Institute's August 2025 workforce report.

Eleven percent is meaningful. It is not an inevitability. Solo practice at triple that share, more than a decade into the most aggressive capital deployment dental has ever seen, tells you the model has real limits: dentistry is local, labor-intensive, and relationship-driven, and none of those traits reward central management the way imaging centers or dialysis do.

The right conclusion is not that DSOs are failing. Plenty are well run and will keep growing. The conclusion is that you are not racing a closing door. You have time, which is the one asset a nervous buyer does not have.

Colorado Is the Regulatory Bill Starting to Arrive

There's a second pressure on platform valuations that owners rarely price, and it's getting louder. Colorado's new rule barring DSOs from serving as the proprietor of a dental practice took effect June 30, 2026, then was stayed on August 24, 2026 after the Association of Dental Service Organizations appealed, per the Colorado Dental Association. That's Rule 1.7, flowing from SB25-194.

One state, one stay, one appeal. But it's a live test of whether the management-services-organization structure that every PE dental platform depends on survives contact with a regulator that decides to look closely at who actually owns the practice. Underwriters notice litigation like this. Lenders notice it faster. Structural uncertainty in a few states is enough to shave a turn off what a buyer will pay for a multi-state platform, and platform multiples set the ceiling on yours.

If you're selling, this cuts against you in the near term. If you're staying, it's one more reason the nervousness in the room is not yours.

$176,110 Is the Number That Squeezes the Model

The last piece of the squeeze is labor, and it hits DSO economics harder than it hits yours. The Bureau of Labor Statistics puts the 2025 median annual wage for dentists at $176,110 across 161,400 dentist jobs, with employment projected to grow 6% from 2025 to 2035.

A platform that bought your practice on an assumption of 30% associate comp needs associates who will accept it, in your zip code, long-term, at scale. Growing demand for dentists against a median already at $176,110 is exactly the setup where that assumption breaks. When it breaks, the adjusted EBITDA the buyer paid you a multiple on was overstated on the day of closing, and the fix comes out of production targets, hygiene scheduling, and the case mix your name is still attached to.

You, by contrast, own your own labor. That's not a small edge in a tight market. It's the whole edge.

What to Do Before the Next Broker Letter

Calculate your adjusted EBITDA this week, the way a buyer would: collections minus all overhead minus a market associate comp figure for your own production. That one number, not your tax return, is your actual market position. Then get a written term sheet before you get emotionally committed to any multiple, and read the cash-at-close line first, the rollover percentage second, and the earnout conditions third. If cash at close is under 65% of the headline price, treat the headline as fiction.

We're tracking two things that would change this call. If the Colorado stay resolves in the ADSO's favor and large platform exits start clearing again at 2021-era multiples, holding becomes the expensive choice and we'll say so. And if that 11% figure in the next ADA workforce report jumps meaningfully, the limits of the model are weaker than we think. Until then, the nervousness belongs to the buyer. Don't let a broker convince you it's yours.

If you want to see what a buyer would actually pay for your practice, run your own adjusted EBITDA and a realistic multiple range against your real collections and overhead before anyone sends you a term sheet. Run your own numbers with our free valuation calculator and find out whether the number in your head survives the subtraction.